We read with great interest the recent article by Ramdani and colleagues in The Journal of Rheumatology on a nationwide multicenter, retrospective study conducted in France describing the status of the occurrence of IgA vasculitis (IgAV) after coronavirus disease 2019 (COVID-19) vaccination.¹ We support and appreciate the authors’ work and agree with their conclusions that IgA vasculitis following COVID-19 vaccination is usually benign and that a fortuitous link cannot be ruled out and now…
J Rheumatol. 2023 Mar 15:jrheum.221189. doi: 10.3899/jrheum.221189. Online ahead of print.
ABSTRACT
We read with great interest the recent article by Ramdani and colleagues in The Journal of Rheumatology on a nationwide multicenter, retrospective study conducted in France describing the status of the occurrence of IgA vasculitis (IgAV) after coronavirus disease 2019 (COVID-19) vaccination.1 We support and appreciate the authors’ work and agree with their conclusions that IgA vasculitis following COVID-19 vaccination is usually benign and that a fortuitous link cannot be ruled out and now requires a worldwide pharmacovigilance study, but there are some concerns about some of the details in the article.
PMID:36921974 | DOI:10.3899/jrheum.221189
English
Arabic
Russian
French
Chinese (Simplified)
Japanese
Portuguese
Spanish